#United States #San Francisco #Cancer Treatment #Shasqi #CAPAC

Shasqi's Presentation at the J.P. Morgan Healthcare Conference

On January 8, 2025, Shasqi, Inc., a leader in the biotechnology sector focused on enhancing cancer therapies through innovative click chemistry, confirmed its participation in the prestigious 43rd Annual J.P. Morgan Healthcare Conference. The event is set to take place on January 16, at 11:00 AM Pacific Time / 2:00 PM Eastern Time in conference hall Elizabethan C. The company’s founder and CEO, José M. Mejía Oneto, MD, PhD, will be the key presenter.

Shasqi has garnered attention for its unique Click Activated Protodrugs Against Cancer (CAPAC®) technology, which represents a breakthrough in targeted cancer therapies. This innovative method leverages a pre-targeting strategy that utilizes in vivo click chemistry to separate drug binders from their therapeutic payloads. By reuniting these components specifically at tumor sites, Shasqi aims to achieve superior activation of potent cancer drugs with minimized side effects that are often associated with traditional therapies such as antibody-drug conjugates (ADCs).

Dr. Mejía Oneto expressed enthusiasm regarding the upcoming presentation, stating, “We are honored to showcase our groundbreaking progress at this year’s J.P. Morgan Healthcare Conference. With CAPAC, we can accurately activate robust cancer treatments directly at the tumor site, a feat not achievable with traditional ADCs. Our lead asset, combined with the CEACAM5 binder and MMAE payload, is demonstrating remarkable preclinical efficacy, which we are eager to unveil during the conference.”

Understanding CAPAC

CAPAC is designed to provide targeted drug delivery that enhances therapeutic efficacy while reducing off-target effects. The technology comprises two main components: a clickable binder that attaches specifically to cancer cells, and a clickable payload that acts as the therapeutic agent. These elements are deliberately separated during circulation within the body, allowing for reduced toxicity to normal tissues. Once they reach the tumor site, the components are reunited through click chemistry, resulting in a potent active therapeutic payload unleashed directly at the cancerous cells.

This sophisticated drug delivery system not only broadens the range of potential therapeutic targets but also expands the therapeutic window of antibody-drug conjugates and radiopharmaceuticals. The transformative potential of CAPAC reinforces Shasqi's commitment to improving cancer treatment outcomes through pioneering biotechnology.

Invitation to Collaborate

Shasqi's team is eager to engage with conference attendees and other industry professionals. Those interested in discussing potential partnerships or learning more about the CAPAC technology are encouraged to reach out to Mukul Agarwal, Shasqi's Chief Business Officer, at [email protected]

For more details on Shasqi and CAPAC, please visit their official website at www.shasqi.com and follow their updates on LinkedIn.

As the landscape of cancer treatment continues evolving, Shasqi’s groundbreaking approach exemplifies the potential for innovation in drug delivery technologies that could soon revolutionize the oncology field.